Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.11 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including microglia; strongest in neutrophil progenitors | 0.75 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 5 Parkinson's papers of 820 | 0.76 |
| pathways Reactome | 9 pathways; mostly immune signalling | 0.90 |
Knock down and overexpress CYBB in microglia; measure IL-1β and TNF release and surface HLA-DR and uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release).
- Cell type
- microglia
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- IL-1β and TNF release and surface HLA-DR
- Functional readout
- uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release)
- Rule-out
- If neither arm moves IL-1β by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of CYBB in iPSC-derived microglia (iMGL); n = 3 differentiations; readouts: IL-1β and TNF release and surface HLA-DR; uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release). Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- CYBB in dopamine neurons, braak-0.40 (p 0.287) → +0.40 (p 0.284)receipt 2415
- CYBB in microglia, braak-0.13 (p 0.732) → -0.21 (p 0.583)receipt 2414
Swarm cases
receipt 2415: CYBB in dopamine neurons, braak
- power
- full sample -0.02 (p 0.949, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.05 (p 0.834, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.08 (p 0.754, n 18). could be the mix.
- skeptic
- leave-one-out range -0.14 to +0.10, sign flips 9; without severely affected donors -0.02 (p 0.949, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CYBB in dopamine neurons.
case closed: nothing better to follow up.
receipt 2414: CYBB in microglia, braak
- power
- full sample -0.24 (p 0.341, n 18), 95% CI -0.63 to +0.26. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.28 (p 0.265, n 18). does not hold up.
- composition
- microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.21 (p 0.408, n 18). could be the mix.
- skeptic
- leave-one-out range -0.42 to -0.13, sign flips 0; without severely affected donors -0.24 (p 0.341, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CYBB in microglia.
case closed: nothing better to follow up.
Receipts
loading the receipts